Lyell Immunopharma furnishes investor presentation; no substantive content in filing

Lyell Immunopharma, Inc.

Filing under Item 7.01 announces a September 11, 2023 investor presentation.
Presentation available on company IR website; attached Exhibit 99.1 lacks slide content.
No financial data, pipeline updates, or guidance provided in this 8-K.
Disclosure is routine FD with no material new information for investors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.